Table 1.
Patient characteristics, overall PSMA-RADS scores, and correlative data (n = 15)
| No | Age (y) | Biopsy ISUP | Pre-RP PSA | Clinical stage | Risk-groupa | RP ISUP | EPE | SVI | Lymph nodes dissected/positive | Tracer | Overall PSMA-RADS | 1st PSA (ng/ml) |
2nd PSA (ng/ml) | Correlative modalities | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 62 | 2 | 5.5 | T1c | 1 | 2 | n | n | 7/0 | 18F-PSMA-1007 | 3B | 0.04 | 0.07 | MRI, CT | |
| 2 | 69 | 2 | 5.1 | T2b | 1 | 2 | y | y | 9/0 | 68 Ga-PSMA-11 | 3B | 0 | 0 | Rib cage X-ray | |
| 3 | 76 | 3 | 15 | T1c | 2 | 3 | y | y | 13/0 | 68 Ga-PSMA-11 | 4 | 1.4 | n/ab | MRI, follow-up PSMA PET/CT | |
| 4 | 74 | 3 | 5 | T1c | 2 | 3 | y | n | 8/0 | 68 Ga-PSMA-11 | 3B | 0.09 | 0.09 | None | |
| 5 | 64 | 2 | 4.5 | T1c | 3 | 2 | n | n | 12/0 | 68 Ga-PSMA-11 | 3B | 0.09 | 0.09 | Follow-up PSMA PET/CT | |
| 6 | 73 | 3 | 16 | T2a | 2 | 2 | Y | n | 9/0 | 18F-PSMA-1007 | 3B | 0 | 0 | None | |
| 7 | 57 | 1 | 10.5 | T2a | 1 | 2 | n | n | 20/0 | 18F-PSMA-1007 | 3B | 0 | 0 | MRI | |
| 8 | 56 | 2 | 12.13 | T2b | 2 | 2 | y | n | 21/0 | 68 Ga-PSMA-11 | 3B | 0 | 0 | MRIc | |
| 9 | 69 | 3 | 10 | T2b | 2 | 3 | y | n | 19/0 | 68 Ga-PSMA-11 | 3B | 0.54 | 0.81 | MRI, follow-up PSMA PET/CT | |
| 10 | 46 | 2 | 13 | T1c | 2 | 2 | y | n | 21/0 | 68 Ga-PSMA-11 | 3B | 0 | 0 | Histopathology | |
| 11 | 70 | 2 | 6.3 | T1c | 1 | 3 | y | n | 14/0 | 68 Ga-PSMA-11 | 3B | 0 | 0 | None | |
| 12 | 51 | 3 | 25 | T3 | 3 | 3 | y | y | 14/1 | 68 Ga-PSMA-11 | 3B | 2.9 | 4.1 | MRI, follow-up PSMA PET/CT | |
| 13 | 72 | 4 | 6.5 | T1c | 3 | 4 | y | n | 7/1 | 68 Ga-PSMA-11 | 5 | 3 | 22 | Follow-up PSMA PET/CT | |
| 14 | 74 | 3 | 9 | T1c | 2 | 3 | n | n | 14/0 | 68 Ga-PSMA-11 | 3B | 0 | 0 | None | |
| 15 | 63 | 2 | 7 | T1c | 1 | 3 | y | n | 17/0 | 68 Ga-PSMA-11 | 3B | 0 | n/a | Follow-up PSMA PET/CT | |
RP radical prostatectomy, ISUP International Society of Urological Pathology, EPE extraprostatic extension, SVI seminal vesicle invasion, MRI magnetic resonance imaging
aNCCN risk group: 1 = favorable intermediate; 2 = unfavorable intermediate; 3 = high
bPatient already started on systemic therapy with PSA reduction
cMRI findings inconclusive. However, a CT scan performed 10 years earlier showed the same finding, supporting a nonprostatic etiology